Website: Sosei Heptares
Sosei Heptares is an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and Structure-Based Drug Design platform capabilities. Sosei Heptares is advancing a broad and deep pipeline of partnered and in-house drug candidates in multiple therapeutic areas including neurology, immuno-oncology, gastroenterology, inflammation and rare/specialty diseases. Partners and collaborators include AstraZeneca, Allergan, Pfizer, Novartis, PeptiDream, Kymab, Daiichi-Sankyo, MorphoSys and Fujifilm. Sosei Heptares is headquartered in Tokyo, Japan, with state-of-the-art R&D facilities in Cambridge, UK and Zürich, Switzerland. Sosei Heptares is a world-leader in stabilizing G Protein-Coupled Receptors (GPCRs). Our patent-protected technologies enable unique structural insights into GPCRs as drug targets. As such, we have the ability and the know-how to design new therapeutic agents with optimized pharmacology using Structure-Based Drug Design (SBDD). Our approach delivers drug candidates with improved physicochemical properties, as well as the potential for enhanced safety and efficacy profiles, and could reduce clinical attrition rates.
Key research facilities, infrastructure and equipment
Heptares Therapeutics maintains cutting edge facilities that enable leveraging of its deep GPCR expertise and fully-integrated drug discovery platform. The presence of all facets of modern drug discovery from molecular biology to translational sciences and development, and access to state-of-the-art facilities (incl. computer-aided drug design labs, computational 3D design laboratory, GPU & CPU clusters, synthesis labs, biochemical and biophysical screening platform, protein production and protein crystallization facilities) have enabled Heptares Therapeutics to become a world leader in its field.
Previous and current involvement in research and training programmes
1) BBSRC iCase DTP and EPSRC Centre for Doctoral Training (CDT) with University of Cambridge;
2) MRC MICA scheme with University of Nottingham;
3) EPSRC IMPACT with University College London;
4) K4DD IMI program;
5) CdG (coinitiator, vice chair of GLISTEN; GPCR-Ligand Interactions, Structures, and Transmembrane Signalling: a European Research Network.
Key persons and expertise
Dr. Chris de Graaf - Head Computational Chemistry Heptares Therapeutics from April 2018, after 9 years Ass. Prof. Computational Medicinal Chemistry at VU University Amsterdam (incl. supervision 6 PhD students), experience in computational chemistry, structural cheminformatics, and computer-aided drug discovery and design.
Dr. Rob Smith Senior Scientist II Computational Chemistry Heptares Therapeutics from, , experience in computational chemistry, cheminformatics, computer-aided drug discovery and design.
Dr. Ben Tehan Associate Director Computational Chemistry / Program Leader with 16 years industrial experience, 7 years GlaxoSmithKline (leader of membrane modelling workgroup) and 9 years Heptares Therapeutics, working exclusively on membrane bound proteins, heading up one internal Program and Deputy on another. Organiser and chair of chemistry/computational chemistry matrix meetings.